Although there are some FDA-approved drugs used in treating multiple myeloma with the strategy to suppress NF-κB, theses agents have been thwarted by side effects including nephrotoxicity, neuropathy, and the malignancy (Mina et al., 2016). This evidence concerns the gene NFKB1 and AL amyloidosis.